Please login to bookmarkClose

A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company’s lawyers sent an email with the wrong opposition deadline.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au